130309-46-5

Basic information

• Product Name: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID
• Synonyms: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID;4-N-BOC-AMINOCYCLOHEXANE CARBOXYLIC ACID;4-TERT-BUTOXYCARBONYLAMINO-CYCLOHEXANECARBOXYLIC ACID;4-(tert-Butoxycarbonylamino)cyclohexanecarboxylic Acid (cis- and trans- mixture);1-(t-Butyloxycarbonylamino)cyclohexyl-4-carboxylic acid;4-[(tert-Butoxycarbonyl)amino]cyclohexane-1-carboxylic acid;4-Aminocyclohexane-1-carboxylic acid, N-BOC protected;Cyclohexanecarboxylicacid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-
• CAS NO: 130309-46-5
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Mol File: 130309-46-5.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 396.7 °C at 760 mmHg
• Flash Point: 193.7 °C
• Appearance: /
• Density: 1.12
• Vapor Pressure: 2.12E-07mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: 2-8°C
• Solubility: Soluble in methanol and tetrahydrofuran(THF).
• PKA: 4.76±0.10(Predicted)
• CAS DataBase Reference: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID(130309-46-5)
• EPA Substance Registry System: 4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID(130309-46-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 130309-46-5(Hazardous Substances Data)

Usage

Uses

4-(Boc-amino)cyclohexanecarboxylic acid is used as pharmaceutical intermediate.

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-8(5-7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 
• 150-13-0 4-amino-benzoic acid 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 603130-12-7 1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol 
• 881657-40-5 tert-butyl ((3R,6S)-6-formyltetrahydro-2H-pyran-3-yl)carbamate 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 38446-95-6 4-oxocyclohexanecarboxylic acid tert-butyl ester 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1776-53-0 4-aminocyclohexanecarboxylic acid 
• 77-92-9 citric acid 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 175867-59-1 methyl 4-aminocyclohexane-1-carboxylate 

Downstream Products

• 503817-57-0 methyl 4-{[(tert-butoxy)carbonyl]amino}cyclohexane-1-carboxylate 
• 371114-60-2 {4-[5-(5-tert-butyl-oxazol-2-ylmethylsulfanyl)-thiazol-2-ylcarbamoyl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 400898-94-4 trans-(4-formylcyclohexyl)methylcarbamic acid tert-butyl ester 
• 400899-08-3 tert-butyl ((1r,4r)-4-(hydroxymethyl)cyclohexyl)(methyl)carbamate 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 400899-12-9 methyl-[4-(3-oxo-propyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 400899-11-8 [4-(3-hydroxy-propyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-10-7 3-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-propionic acid ethyl ester 
• 400899-16-3 [4-(5-hydroxy-pentyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-17-4 methanesulfonic acid 5-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-pentyl ester 
• 878395-72-3 4-amino-cyclohexanecarboxylic acid [2-(cyclopentanecarbonyl-amino)-benzothiazol-6-yl]-amide 
• 304873-80-1 (4-formyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 505093-89-0 (4S)-3-[cis-(4-t-butoxycarbonylaminocyclohexyl)propenoyl]-4-phenylmethyl-2-oxazolidinone 

Relevant articles and documents

Rigid aromatic linking moiety in cationic lipids for enhanced gene transfection efficiency

Although numerous cationic lipids have been developed as non-viral gene vectors, the structure-activity relationship (SAR) of these materials remains unclear and needs further investigation. In this work, a series of lysine-derived cationic lipids contain

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors

In this study, a series of novel hydroxyamidine derivatives were identified as potent and selective IDO1 inhibitors by structure-based drug design. Among them, compounds 13-15 and 18 exhibited favorable enzymatic and cellular activities. Compound 18 showed improved bioavailability in mouse, rat, and dog (F% = 44%, 58.8%, 102.1%, respectively). With reasonable in vivo pharmacokinetic properties, compound 18 was further evaluated in a transgenic MC38 xenograft mouse model. The combination of compound 18 with PD-1 monoclonal antibody showed a synergistic antitumor effect. These data indicated that compound 18 as a potential cancer immunotherapy agent should warrant further investigation.

BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF

The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat